Nadezhda S. Dolgova

Nadezhda S. Dolgova

Auto-generated profile, based on publicly available information

Nadezhda S. Dolgova

Altai State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Bulletin of Medical Science
Verified
Journal Article
Closed access
NDN.S. Dolgova
N.S. Dolgova
SYS.D. Yavorskaya
S.D. Yavorskaya
EME.V. Mikhalev
E.V. Mikhalev
YKYu.V. Korenovskiy
Yu.V. Korenovskiy
ESE.V. Suzopov
E.V. Suzopov
KDK.V. Dmitrienko
K.V. Dmitrienko

1 January 2026 in Bulletin of Medical Science
Verified
Journal Article
Open access
SYSvetlana D. Yavorskaya
Svetlana D. Yavorskaya
OROlga V. Remneva
Olga V. Remneva
NDNadezhda S. Dolgova
Nadezhda S. Dolgova
KDKseniya V. Dmitrienko
Kseniya V. Dmitrienko
ALAnastasia I. Lebedeva
Anastasia I. Lebedeva
Objective. To evaluate the clinical efficacy and safety of a herbal drug combination manufactured by Alfit Plus compony (Fitol-1 Mastoprof capsules + Mastokrel cream gel) as monotherapy in reproductive-aged patients with ultrasound signs of benign breast dysplasia and mastalgia. Materials and Methods. A single-center, open, prospective, pre-post comparative study was conducted. The study included 30 patients aged 21 to 45 years with mastalgia (VAS intensity >40 mm) and ultrasound signs of benign breast dysplasia corresponding to BIRADS category 2. Exclusion criteria were BIRADS ≥3, the use of hormonal medications, and severe somatic pathology. At baseline and after 3 months, the following parameters were evaluated: complaints, pain intensity using VAS, breast ultrasound data (on days 7–9 of the menstrual cycle), anthropometric measurements, blood pressure, and heart rate. Patients received Fitol-1 Mastoprof (1 capsule twice daily, per os) and Mastokrel cream gel (applied to the breasts morning and evening) for 3 months. Statistical analysis was performed using paired Student's t-test and χ² test (significance set at p<0.05). Results. The mean age was 37.0 ± 7.29 years; normal menstrual cycle was present in 70.0% of the cases. The baseline intensity of mastalgia according to VAS was – 53,5 ± 15,258 mm. Ultrasound revealed diffuse changes in all patients, small cysts (3–7 mm) in 60.0%, and duct ectasia in 15.0%. After 3 months of therapy, mastalgia persisted in only 6 patients (20.0%) with a reduction in intensity to 16, 66 ± 3, 47 mm (p <0.001); the mean VAS score for the entire group was 3.3 ± 0.42 mm. Galactorrhea was not observed in any patient. Ultrasound findings improved in 76.6% of cases (p <0.001): cysts regressed in 12 of 18 patients, and duct ectasia persisted in only 1 of 15 patients. No adverse events were reported and all patients noted the convenience of the treatment regimen. Conclusion. Three-month monotherapy with the combination of Fitol-1 Mastoprof (capsules) and Mastokrel cream gel in reproductive-aged patients with benign breast dysplasia allows complete resolution or significant reduction of mastalgia in 80% of cases, improves ultrasound findings in 76.6% and is not associated with adverse events. The results obtained support the use of this combination patients with mastalgia and benign breast dysplasia.

11 May 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
MIM. B. Igitova
M. B. Igitova
SYS. D. Yavorskaya
S. D. Yavorskaya
KDK. V. Dmitrienko
K. V. Dmitrienko
NDN. S. Dolgova
N. S. Dolgova
Introduction . Preterm birth remains one of the unresolved medical and social problems, with about 70% of cases occurring as late preterm births between 34 and 36 weeks and 6 days of gestation. Infectious factors play a significant role in preterm birth, but their role in the late preterm birth pathogenesis has been insufficiently studied. Aim . To determine the significance of infectious and inflammatory risk factors in the pathogenesis of late spontaneous preterm birth. Materials and methods . A retrospective single-center cohort comparative study was conducted. We analysed data from the medical records of 300 women with singleton pregnancies, including 150 with spontaneous late preterm birth (group 1) and 150 who delivered at 37–41 gestation weeks (group 2). Statistical data were processed using MedCalc Version 18.2.1 software (license Z2367-F3DD4-83E2E8-A6963-ED902) with nonparametric statistical methods. The critical level of statistical significance was set at p ≤ 0.05. Results . Age, medical, social history and obstetric parity in patients of the comparison groups were comparable. Infectious and inflammation risk factors for spontaneous late preterm birth are vaginal infections during pregnancy (OR = 3.59; 95% CI 2.09–6.2; p < 0.0001), acute somatic bacterial infections (OR = 2.1; 95% CI 1.14–3.87; p = 0.018) and acute respiratory viral diseases (OR = 3.15; 95% CI 1.74–5.69; p = 0.0001). In the presence of two or more episodes of acute infection diseases during gestation, the late preterm birth probability increases up to 4 times (OR = 4.19; 95% CI 2.25–7.78; p < 0.0001). Conclusion. Acute inflammatory diseases during pregnancy (both genital and somatic) are the most important among the factors for spontaneous late premature birth risk, which dictates the need for the treatment on infection foci at the pregnancy planning stages.